In addition, HAS2 expression negatively correlated with amylo-α-1,6-glucosidase-4-α-glucanotransferase (AGL), one of the enzymes catalyzing glycogenolysis, which has been described as a tumor growth suppressor and prognostic marker in human BC [203]. The gene discussed is AGL; the disease is breast cancer.